Oak Ridge Investments LLC Lowers Stock Holdings in Hims & Hers Health, Inc. $HIMS

Oak Ridge Investments LLC cut its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 51.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,430 shares of the company’s stock after selling 31,617 shares during the quarter. Oak Ridge Investments LLC’s holdings in Hims & Hers Health were worth $1,726,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ethic Inc. purchased a new position in Hims & Hers Health in the second quarter valued at approximately $348,000. Carnegie Investment Counsel raised its stake in shares of Hims & Hers Health by 25.4% in the 3rd quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock valued at $17,238,000 after acquiring an additional 61,560 shares during the period. Intellectus Partners LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter valued at $3,043,000. Occidental Asset Management LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter valued at $305,000. Finally, Dakota Wealth Management purchased a new stake in Hims & Hers Health during the 2nd quarter worth $354,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $31.38 on Friday. Hims & Hers Health, Inc. has a 52 week low of $23.97 and a 52 week high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The stock has a market cap of $7.14 billion, a P/E ratio of 58.11, a price-to-earnings-growth ratio of 5.32 and a beta of 2.37. The stock has a 50 day moving average of $35.79 and a 200-day moving average of $45.68.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same period in the prior year, the company earned $0.32 earnings per share. The company’s revenue was up 49.2% on a year-over-year basis. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has approved a stock buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares in the company, valued at approximately $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Chi sold 13,750 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at approximately $11,202,460.31. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 125,544 shares of company stock valued at $4,620,821. Corporate insiders own 13.71% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on HIMS. UBS Group set a $32.00 price objective on Hims & Hers Health in a research note on Tuesday, November 4th. Barclays started coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. KeyCorp assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They issued a “sector weight” rating for the company. BTIG Research reissued a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Finally, Evercore ISI started coverage on shares of Hims & Hers Health in a report on Monday, January 12th. They set an “in-line” rating and a $33.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $44.54.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.